Inventiva Sa · EURONEXT:IVA
Inventiva Sa — FY2025 Earnings Presentation
14 slides from Inventiva Sa's earnings presentation, Mar 31, 2026
Slide 1: 2025 Full-Year Financial Results
2025 Full-Year Financial Results March 31, 2026
Slide 2: Disclaimer
Disclaimer This presentation contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included in this presentation are forward-looking statements. These s
Slide 3: Agenda
Agenda 1. Corporate overview 2. Lanifibranor clinical program update 3. 2025 FY highlights 4. Q&A 3
Slide 4: Structured to Deliver Topline Results Expected in Q4 2026 and Prepare for Potential Launch
Structured to Deliver Topline Results Expected in Q4 2026 and Prepare for Potential Launch Pipeline Prioritization • Pipeline prioritization plan in 2025 • Sold global rights to odiparcil to Biossil: upfront payment + potential regulatory Building a capital- and commercial milestones up to $90M and
Slide 5: Underdiagnosed and Undertreated, with Rapidly Expanding Commercial Validation
Underdiagnosed and Undertreated, with Rapidly Expanding Commercial Validation Treatable MASH Population We believe ~18M Total MASH Population1 Inventiva is +25% well-positioned to Only 10% of the Compared ~1.9M Diagnosed MASH Population2 overall patient to the 2024 estimate potentially bring populat
Slide 6: Rational Pan-PPAR Design Informed by Decades of Biology
Rational Pan-PPAR Design Informed by 150 Decades of Biology 125 hPPAR Lanifibranor: Low-potency, balanced PPAR-α/δ/γ activation designed to % Activation 100 hPPAR avoid receptor dominance 75 hPPAR 50 1st 25 0 -10 -8 -6 -4 First-in-class new Balanced and low potency Balanced PPAR Differentiated Lanif
Slide 7: PPARs Enable Coordinated Modulation of the Metabolic, Inflammatory, and Fibrotic Pathways at the Core of MASH
PPARs Enable Coordinated Modulation of the Metabolic, Inflammatory, and Fibrotic Pathways at the Core of MASH Steatosis (abnormal fat buildup) Fibrosis PPARγ PPARγ, PPARα Fatty acid uptake Stellate cell proliferation and activation LIVER Fatty acid breakdown (catabolism) Collagen and fibronectin pro
Slide 8: NATIVE Phase 2b Trial Results Support Antifibrotic Activity with Broader Metabolic Impact
NATIVE Phase 2b Trial Results Support Antifibrotic Activity with Broader Metabolic Impact 24% effect size on the 18% effect size on dual endpoint of improvement in fibrosis fibrosis improvement with no worsening of MASH and MASH resolution versus placebo 24 weeks Histologic improvement observed alon
Slide 9: NATiV3 Design Anchored in NATIVE Outcomes
NATiV3 Design Anchored in NATIVE Outcomes Dose, population, and endpoints aligned with NATIVE to preserve observed NATiV3 Clinical Trial treatment effect. Primary Endpoint Composite end point of patients having Main Cohort both MASH resolution and 1 stage of 72 weeks of treatment End of fibrosis imp
Slide 10: NATiV3 Population Consistent with NATIVE, Reflecting Contemporary MASH
NATiV3 Population Consistent with NATIVE, Reflecting Contemporary MASH Higher diabetes prevalence and more advanced fibrosis Demographics & Metabolic Profile Liver Disease Profile Co-medications 75% 67.0% 59% 58% 65% 41.3% 41% 42% 33% 34.8% 97.10 93.30 50 51 40 37 10.0% (± 23.6) (± 18.8) 2.8% Female
Slide 11: Topline Data Expected in Q4 2026
Topline Data Expected in Q4 2026 April 2025 Last patient Randomized 1009 in main cohort 410 in exploratory cohort Potential Launch 2025 2026 2027 2028 Lanifibranor Q4 2026 H1 2027 Expected topline Expected NDA filing results with FDA 11
Slide 12: Inventiva's 2025 Income Statement
Inventiva’s 2025 Income Statement Year Ended (in thousands of euros) December 31, 2025 December 31, 2024 Revenues 4,483 9,198 Other income 3,443 5,526 Research and development expenses (87,043) (90,880) Marketing – business development expenses (4,963) (1,953) General and administrative expenses (47
Slide 13: Pioneering the Future of MASH
Pioneering the Future of MASH Novel investigational Phase 2b showed Phase 2b showed Phase 3 topline data pan-PPAR agonist 18% effect size on 24% effect size on readout anticipated engages the core drivers improvement of fibrosis improvement of fibrosis in Q4 2026 of fibrosis progression with no wors
Slide 14: Thank You
Thank You Contacts: Inventiva Inventiva Pascaline Clerc David Nikodem Executive VP, External and Corporate Affairs Head of Investor Relations pascaline.clerc@inventivapharma.com david.nikodem@inventivapharma.com +1 202 499 8937 +1 917 282 8521 ICR Healthcare ICR Healthcare Alexis Feinberg Patricia L